anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an astaxanthin nano preparation prepared by an electrostatic spraying method and a preparation method thereof, and relates to the field of nano pharmaceutical preparations. The astaxanthin solid nanometer preparation is prepared by a coaxial electrostatic spraying method through dissolving a medicine, a hydrophilic polymer carrier and an absorption promoting component in a nuclear layer mixed solvent and dissolving the hydrophilic polymer carrier in water. Wherein the mass ratio of the astaxanthin, the hydrophilic polymer carrier and the absorption promoting component in the nuclear layer solution is 1:0-8:2-4, the total concentration of the hydrophilic polymer carrier and the absorption promoting component in the nuclear layer solution is 0.2-1.2% (w/v), and the total concentration of the shell layer carrier is 0.6-2.6% (w/v). The volume ratio of the core layer solution to the shell layer solution was 1:1 (v/v). The nanometer preparation has the advantages of significantly increased astaxanthin solubility, increased in vitro release rate, and improved oral bioavailability. The method has the advantages of simple process and high industrialization degree, and the prepared astaxanthin solid nano preparation has uniform particle size, stable properties and good application prospect.
Participants will receive virtual reality for 30 minutes before bedtime then will be placed on an eye mask and combine with the sleep promotion routine. The intervention duration need continues for two days or until discharge from ICU.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to therapy, namely pediatrics, general medical practice, dermatology and immunology, and can be used to treat psoriasis. For this, first, the centers of chronic infection of the ENT organs are sanitized by local cryotherapy. After this, against the background of medical therapy of psoriasis, a general cryotherapy (OCT) is performed in an open loop cryocamera. In this case, the first OCT procedure is carried out at a temperature of -120 °C for a duration of 1–2 minutes. Subsequent OCT procedures are performed with a decrease in the temperature of the internal environment of the cryocamera to -150…-190 °C with an increase in the duration of the procedure up to 3 minutes. OCT rate is 14–20 daily procedures. In addition, after 5–10 minutes after the patient exits the cryocamera cryodestruction of psoriatic plaques is performed by local contact cryotherapy at a temperature of -140 °C to -170 °C and exposure time 1–2 minutes per 1 dmthe affected area of the skin to the stage of the white ischemic spot. After completion of OCT, contact cryotherapy treatment is continued until the plaques are completely cleansed of flakes and the hyperkeratosis is reduced, and affects the spots of pigmentation that appear at the site of the plaque in psoriasis. In this case, local cryotherapy is performed by a dry air jet at an outlet temperature of -170 °C at a distance of 2–4 cm from the nozzle, processing the selected area of the patient's body surface at the rate of 1–2 minutes per 1 dmin mode of decreasing the number of procedures – every day until the onset of pigmentation, a day before the appearance of stable pigmentation, 1–2 times a week until the skin is completely cleansed.EFFECT: method ensures reduction of treatment time, stabilization of clinical manifestations of psoriasis, shortening the time to achieve a positive result and lengthening the periods of primary remission, a sharp decrease in the intensity of clinical manifestations with repeated exacerbation of psoriasis without the use of detoxification therapy, antihistamines and hepatoprotectors.1 cl, 5 ex
The aim of this article is to determine the efficacy of otoendoscopy during microscopic cholesteatoma surgery on residual cholesteatoma rates postoperatively. The medical records of patients (aged 4-90) with primary acquired cholesteatoma who underwent microscopic cholesteatoma surgery (exclusively transcanal approach or canal wall-up tympano-mastoidectomy) with subsequent otoendoscopic examination (80 ears) for intraoperative cholesteatoma residues were retrospectively reviewed. All cases with mixed microscopic/endoscopic, fully endoscopic, or fully microscopic dissection were excluded, as well as cases where a canal wall-down technique was used. After microscopic cholesteatoma removal, the otoendoscope was used to inspect the middle ear recesses for intraoperative cholesteatoma residues. The intra- and postoperative cholesteatoma residue rate were evaluated. On endoscopic examination, intraoperative cholesteatoma residues were encountered in 24 patients (30%). A total of 30 foci were detected. Most of them were found in the superior retrotympanum (15 foci). In 9 cases an antral remnant guided the surgeon to convert to a canal wall up tympanomastoidectomy. During the postoperative follow-up period, residual cholesteatoma was detected on postoperative magnetic resonance imaging in 6 patients (7.5%). Adding an otoendoscopic examination to microscopic cholesteatoma surgery reduced the postoperative cholesteatoma residues rate (odds ratio=0.16). A negative otoendoscopic examination led to a cholesteatoma residue-free follow-up period in 95% of cases(NPV=0.95). Otoendoscopy is effective in identifying intraoperative cholesteatoma residues after microscopic cholesteatoma surgery. It reduces the postoperative cholesteatoma residue rate, and a negative otoendoscopic examination increases the likelihood of a cholesteatoma residue-free follow-up.
Mammals typically heal with fibrotic scars, and treatments to regenerate human skin and hair without a scar remain elusive. We discovered that mice lacking C-X-C motif chemokine receptor 2 (CXCR2 knockout [KO]) displayed robust and complete tissue regeneration across three different injury models: skin, hair follicle, and cartilage. Remarkably, wild-type mice receiving plasma from CXCR2 KO mice through parabiosis or injections healed wounds scarlessly. A comparison of circulating proteins using multiplex ELISA revealed a 24-fold higher plasma level of granulocyte colony stimulating factor (G-CSF) in CXCR2 KO blood. Local injections of G-CSF into wild-type (WT) mouse wound beds reduced scar formation and increased scarless tissue regeneration. G-CSF directly polarized macrophages into an anti-inflammatory phenotype, and both CXCR2 KO and G-CSF-treated mice recruited more anti-inflammatory macrophages into injured areas. Modulating macrophage activation states at early time points after injury promotes scarless tissue regeneration and may offer a therapeutic approach to improve healing of human skin wounds.
PURPOSE: Sarcopenia influences the short- and long-term outcomes of various medical conditions including malignancy. Ishii's screening test estimates the probability of sarcopenia based on a score calculated by three simple variables: age, grip strength, and calf circumference. We investigated the clinical significance of Ishii's score for patients with non-metastatic obstructive colorectal cancer (OCRC) who underwent curative surgery after intraluminal decompression.
METHODS: Ishii's score was calculated in 79 patients with OCRC. Muscle volume loss and decreased muscle quality were evaluated by computed tomography (CT) images as skeletal muscle index (SMI) and intramuscular adipose tissue content (IMAC), respectively.
RESULTS: There were 46 men and 33 women, with a median age of 70 years old. The cutoff value for Ishii's score was 155.1 and 15 patients were in the high-score group. The high-score group was significantly associated with worse time to recurrence (TTR) and overall survival (OS), and a high Ishii's score was an independent negative prognostic factor for TTR (hazard ratio = 2.93, P = 0.015). A high Ishii's score was significantly associated with a low SMI value but not with the IMAC value.
CONCLUSION: A high Ishii's score was independently associated with poorer TTR in patients with non-metastatic OCRC.
OBJECTIVE: The impact of CYP2C19 genotype on clopidogrel outcomes is one of the most well established pharmacogenetic interactions, supported by robust evidence and recommended by the Food and Drug Administration and clinical pharmacogenetics implementation consortium. However, there is a scarcity of large-scale real-world data on the extent of this pharmacogenetic effect, and clinical testing for the CYP2C19 genotype remains infrequent. This study utilizes the UK Biobank dataset, including 10 365 patients treated with clopidogrel, to offer the largest observational analysis of these pharmacogenetic effects to date.
METHODS: Incorporating time-varying drug exposure and repeated clinical outcome, we adopted semiparametric frailty models to detect and quantify exposure-based effects of CYP2C19 (*2,*17) variants and nongenetic factors on the incidence risks of composite outcomes of death or recurrent hospitalizations due to major adverse cardiovascular events (MACE) or hemorrhage in the entire cohort of clopidogrel-treated patients.
RESULTS: Out of the 10 365 clopidogrel-treated patients, 40% (4115) experienced 10 625 MACE events during an average follow-up of 9.23 years. Individuals who received clopidogrel (coverage >25%) with a CYP2C19*2 loss-of-function allele had a 9.4% higher incidence of MACE [incidence rate ratios (IRR), 1.094; 1.044-1.146], but a 15% lower incidence of hemorrhage (IRR, 0.849; 0.712-0.996). These effects were stronger with high clopidogrel exposure. Conversely, the gain-of-function CYP2C19*17 variant was associated with a 5.3% lower incidence of MACE (IRR, 0.947; 0.903-0.983). Notably, there was no evidence of *2 or *17 effects when clopidogrel exposure was low, confirming the presence of a drug-gene interaction.
CONCLUSION: The impact of CYP2C19 on clinical outcomes in clopidogrel-treated patients is substantial, highlighting the importance of incorporating genotype-based prescribing into clinical practice, regardless of the reason for clopidogrel use or the duration of treatment. Moreover, the methodology introduced in this study can be applied to further real-world investigations of known drug-gene and drug-drug interactions and the discovery of novel interactions.
The overall goal of this proposal is to better understand the molecular basis and structural and physiologic consequences of airway remodeling in severe asthma and how remodeling changes over time. In that context, the investigators propose to study a well-characterized cohort of adult and pediatric subjects with severe asthma using a multidisciplinary approach that includes state-of-the-art morphometric, imaging, and physiologic measurements of airways. The investigators will contrast these findings to those in groups with well-controlled asthma, normal controls, and diseased controls (chronic bronchitis) to identify features that can provide biologic targets unique to severe asthma. The investigators have demonstrated that epithelial hyperplasia, goblet cell metaplasia and mucin production are features of airway remodeling in subjects with severe asthma, and that epithelial remodeling was due to increased epithelial proliferation and decreased cell death. The investigators propose that individuals with severe asthma, in comparison to well controlled asthma, have: (I) increased airway remodeling as evidenced by goblet cell metaplasia and mucin production, (II) greater airway thickness by multidetector-row CT of the chest (MDCT) leading to ventilation defects demonstrated by hyperpolarized helium (3He) MRI and air trapping demonstrated by MDCT, and (III) airway remodeling associated with more severe and progressive airflow obstruction. The investigators hypothesize that the goblet cell metaplasia and increased mucin The investigators have observed in severe asthma are being driven by an IL-13- and EGFR-dependent mechanism that inhibits epithelial cell apoptosis and allows IL-13 differentiation of the airway epithelium into goblet cells (Aim I). The investigators further hypothesize that this remodeling of segmental airways in severe asthma leads to distal ventilation defects and air trapping (Aim II). In an effort to define potential predictors of subsequent decline in lung function in severe asthma, the investigators hypothesize that baseline airway remodeling as reflected by MDCT airway wall area (AWA%) is predictive of FEV1 (post-corticosteroid/bronchodilator FEV1) decline (Aim III). The identification of potential variables associated with remodeling and severe asthma will help identify individuals at risk whom would benefit from specific targeted therapy. The concerted efforts of this project together with the SARP will lead to new insights on the mechanistic basis for severe asthma, further elucidate how it differs from mild-moderate asthma, identify potential targets for intervention, and will provide imaging metrics to objectively evaluate outcomes for new treatments.
JC virus infection resulting in PML and death can occur in RITUXAN-treated patients with hematologic malignancies or with autoimmune diseases. The majority of patients with hematologic malignancies diagnosed with PML received RITUXAN in combination with chemotherapy or as part of a hematopoietic stem cell transplant. The patients with autoimmune diseases had prior or concurrent immunosuppressive therapy. Most cases of PML were diagnosed within 12 months of their last infusion of RITUXAN.

Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture.

Discontinue RITUXAN and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML.
The efficacy of sumatriptan injection in the acute treatment of cluster headache was demonstrated in 2 randomized, double-blind, placebo-controlled, 2-period crossover trials (Studies 4 and 5). Patients aged 21 to 65 years were enrolled and were instructed to treat a moderate to very severe headache within 10 minutes of onset. Headache relief was defined as a reduction in headache severity to mild or no pain. In both trials, the proportion of individuals gaining relief at 10 or 15 minutes was significantly greater among patients receiving 6 mg of sumatriptan injection compared with those who received placebo (see Table 4).

An estimate of the cumulative probability of a patient with a cluster headache obtaining relief after being treated with either sumatriptan injection or placebo is presented in Figure 1.

Figure 1. Time to Relief of Cluster Headache from Time of Injectiona

a The figure uses Kaplan-Meier (product limit) Survivorship Plot. Patients taking rescue medication were censored at 15 minutes.

The plot was constructed with data from patients who either experienced relief or did not require (request) rescue medication within a period of 2 hours following treatment. As a consequence, the data in the plot are derived from only a subset of the 258 headaches treated (rescue medication was required in 52 of the 127 placebo-treated headaches and 18 of the 131 headaches treated with sumatriptan injection).

Other data suggest that treatment with sumatriptan injection is not associated with an increase in early recurrence of headache and has little effect on the incidence of later-occurring headaches (i.e., those occurring after 2, but before 18 or 24 hours).
FIELD: medicine. ^ SUBSTANCE: cardiac hystiocytes are proliferated by inducing of cyclin and CDK expression in cardiac hystiocytes and by inhibiting function or activity of protein of Cip/Kip family or by inhibiting production of protein of Cip/Kip family. There is described expression vector that contains a cyclin gene, a cyclin-dependent kinase gene and one or several agents chosen from the group consisting of a gene coding the factor which inhibits production, function or activity of protein of Cip/Kip family and nucleic acid sequence which inhibits production of protein of Cip/Kip family. There is disclosed pharmaceutical composition containing said vector, and applied for treatment of cardiac diseases. There is offered cardiac hystiocyte produced by the declared method. There is presented method of treating a cardiac disease that implies injection of the disclosed pharmaceutical composition. ^ EFFECT: regeneration and recovery of cardiac hystiocytes. ^ 31 cl, 13 dwg, 1 tbl, 6 ex
Disclosed herein are methods for the production of mutant bacteriophages with altered host range. Additionally, disclosed herein are methods and systems for rapid detection of microorganisms such as <i>Listeria spp</i>. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as <i>Listeria</i>-specific bacteriophage, allows detection of a specific microorganism, such as <i>Listeria spp</i>. and an indicator signal may be amplified to optimize assay sensitivity.
PURPOSE:To obtain powder for a water and oil repellent cosmetic, blended in a cosmetic and capable of preventing makeup disorder due to the sebum, etc., improving the extensibility of the cosmetic on the skin and imparting good touch to the skin. CONSTITUTION:The objective powder for a water and oil repellent cosmetic is obtained by treating the surface of an N-mono-long-chain acyl basic amino acid having one 8-22C fatty acid acyl group in the molecule, e.g. Nalpha- lauroyllysine, Nalpha-2-ethylhexanoylornithine or Nalpha-palmitoylarginine with a fluorine compound, e.g. a phosphoric acid ester having a perfluoroalkyl group, tetrafluoroethylene resin or a perfluoroalkyl alcohol. The fluorine compound is used in an amount of preferably 0.01-30 pts.wt., especially 0.5-15 pts.wt. based on 100 pts.wt. N-mono-long-chain acyl basic amino acid. This powder for the cosmetic is blended in an amount of preferably 0.1-99wt.%, especially 1-50wt.% in the cosmetic.
The intervention consists of 6 weeks oral administration of CBD oil Gelcaps, starting at a dosage of 15 mg twice per day with up titration to 45 mg twice per day. At any given dose, if participants develop side effects, the dosage will be reduced to the previous dose.
Anemia is sometimes seen in patients receiving NSAIDs, including Dolobid. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including Dolobid, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving diflunisal tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.
Methods and systems for improving healthcare through community engagement are provided. In one embodiment, a method includes initializing a community health application on a computing device for an engagement session with a candidate patient. A client identification sequence is performed using the application to enroll the candidate patient as a new community health client or lookup the candidate patient as an existing community health client. Certain client information is collected from the community health client via interaction with the computing device by a healthcare facilitator during the engagement session. The community health application controlling the computing device by presenting displays and reading data in relation to the displays. The client information is processed to select a clinical sequence for the engagement session with the community health client based on the client information. In another embodiment, the method is directed to processing and distribution of the client information to third parties.
Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
PURPOSE: A system for delivering a tooth whitening substance to a plurality of adjacent teeth is provided, wherein the tooth whitening substance is dispersed within a polymer. Therefore, the system is not sticky when applied, does not need to be removed after use thereof and is conveniently used. CONSTITUTION: A thin film typed delivery system contains 5 to 80% by weight of a polymer, 0.1 to 50% by weight of a tooth whitening substance and additionally a protective film layer(2) with a thickness of 5 to 150μm. The polymer has an adhesion property to the teeth when hydrated by saliva, but no adhesion property thereto when stored. The polymer is one or two or more kinds selected from hydroxypropylmethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone, hydropropyl cellulose, carbomer, a copolymer of methyl vinyl ether and maleic anhydride and polyethylene oxide. The tooth whitening substance is hydrogen peroxide, carbamide peroxide or the mixture thereof.
Control group participants receive usual care between the baseline and 8-week follow-up survey. After completing the follow-up survey, control participants will be invited to take part in an educational workshop about pain and loneliness and will receive all intervention materials.
The invention provides ass-hide glue effervescent granules and a preparation method thereof. The preparation method comprises the following steps: mixing ass-hide glue, a diluent, an effervescent disintegrant and a sweetener, and making into granules with a binder, and drying the granules to obtain the effervescent granules, wherein the effervescent disintegrant consists of an organic acid and sodium bicarbonate. The granules comprise the following components in parts by weight: ass-hide glue 15-20 parts, lactose 1.5-2.5 parts, citric acid 2.0-2.5 parts, sodium bicarbonate 1.8-2.0 parts, acesulfame potassium 0.06-0.10 part, and the binder. The granules are prepared from ass-hide glue and adjuvants by acid-base mixing granulation, and have the advantages of simple production process and stable product. The ass-hide glue effervescent granules are prepared by adding the effervescent disintegrant during preparation, and retain the quality of original ass-hide glue and improve the taste of ass-hide glue. The finished products rapidly dissolve in water (70 DEG C), and have no astringent taste, bitter taste and adhesion.
Advanced cancers are usually debilitating. There are few treatments available for symptoms of advanced cancers like loss of appetite, decreased strength, fatigue, and change in mood. This Phase II, open label study with OHR/AVR118 will enable the Sponsor to gather data on safety and efficacy of OHR/AVR118 in the patient population with anorexia-cachexia. Patients aged 18-85 with advanced cancers (excluding central nervous system \[CNS\] cancers) who may or may not be receiving chemotherapy, may be eligible to participate. The study drug, 4.0 mL, will be given subcutaneously each day for 28 days. Patients who respond to the trial period dosing will be eligible to continue on OHR/AVR118 if they and their physicians believe it would be beneficial, and if no safety concerns are raised.
OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.